['DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS (CYP3A4 INHIBITION)', 'IN VITRO STUDIES DEMONSTRATED POTENTIAL FOR VORICONAZOLE TO INHIBIT METABOLISM (INCREASED PLASMA EXPOSURE)', 'FREQUENT MONITORING FOR ADVERSE EVENTS AND TOXICITY RELATED TO CALCIUM CHANNEL BLOCKERS. ADJUSTMENT OF CALCIUM CHANNEL BLOCKER DOSAGE MAY BE NEEDED.', 'SULFONYLUREA ORAL HYPOGLYCEMICS (CYP2C9 INHIBITION)', 'NOT STUDIED IN VIVO OR IN VITRO , BUT DRUG PLASMA EXPOSURE LIKELY TO BE INCREASED', 'FREQUENT MONITORING OF BLOOD GLUCOSE AND FOR SIGNS AND SYMPTOMS OF HYPOGLYCEMIA. ADJUSTMENT OF ORAL HYPOGLYCEMIC DRUG DOSAGE MAY BE NEEDED.', 'VINCA ALKALOIDS (CYP3A4 INHIBITION)', 'NOT STUDIED IN VIVO OR IN VITRO , BUT DRUG PLASMA EXPOSURE LIKELY TO BE INCREASED', 'FREQUENT MONITORING FOR ADVERSE EVENTS AND TOXICITY (I.E., NEUROTOXICITY) RELATED TO VINCA ALKALOIDS. ADJUSTMENT OF VINCA ALKALOID DOSAGE MAY BE NEEDED.']AL CONTRACEPTIVES CONTAINING ETHINYL ESTRADIOL AND NORETHINDRONE (CYP3A4 INHIBITION)**', 'INCREASED', 'MONITORING FOR ADVERSE EVENTS RELATED TO ORAL CONTRACEPTIVES IS RECOMMENDED DURING COADMINISTRATION.', 'WARFARIN* (CYP2C9 INHIBITION)', 'PROTHROMBIN TIME SIGNIFICANTLY INCREASED', 'MONITOR PT OR OTHER SUITABLE ANTI-COAGULATION TESTS. ADJUSTMENT OF WARFARIN DOSAGE MAY BE NEEDED.', 'OMEPRAZOLE* (CYP2C19/3A4 INHIBITION)', 'SIGNIFICANTLY INCREASED', 'WHEN INITIATING THERAPY WITH VORICONAZOLE IN PATIENTS ALREADY RECEIVING OMEPRAZOLE DOSES OF 40 MG OR GREATER, REDUCE THE OMEPRAZOLE DOSE BY ONE-HALF. THE METABOLISM OF OTHER PROTON PUMP INHIBITORS THAT ARE CYP2C19 SUBSTRATES MAY ALSO BE INHIBITED BY VORICONAZOLE AND MAY RESULT IN INCREASED PLASMA CONCENTRATIONS OF OTHER PROTON PUMP INHIBITORS.', 'OTHER HIV PROTEASE INHIBITORS (CYP3A4 INHIBITION)', 'IN VIVO STUDIES SHOWED NO SIGNIFICANT EFFECTS ON INDINAVIR EXPOSURE IN VITRO STUDIES DEMONSTRATED POTENTIAL FOR VORICONAZOLE TO INHIBIT METABOLISM (INCREASED PLASMA EXPOSURE)', 'NO DOSAGE ADJUSTMENT FOR INDINAVIR WHEN COADMINISTERED WITH VORICONAZOLE FREQUENT MONITORING FOR ADVERSE EVENTS AND TOXICITY RELATED TO OTHER HIV PROTEASE INHIBITORS', 'OTHER NNRTIS***** (CYP3A4 INHIBITION)', 'A VORICONAZOLE-EFAVIRENZ DRUG INTERACTION STUDY DEMONSTRATED THE POTENTIAL FOR VORICONAZOLE TO INHIBIT METABOLISM OF OTHER NNRTIS (INCREASED PLASMA EXPOSURE)', 'FREQUENT MONITORING FOR ADVERSE EVENTS AND TOXICITY RELATED TO NNRTI', 'BENZODIAZEPINES (CYP3A4 INHIBITION)', 'IN VITRO STUDIES DEMONSTRATED POTENTIAL FOR VORICONAZOLE TO INHIBIT METABOLISM (INCREASED PLASMA EXPOSURE)', 'FREQUENT MONITORING FOR ADVERSE EVENTS AND TOXICITY (I.E., PROLONGED SEDATION) RELATED TO BENZODIAZEPINES METABOLIZED BY CYP3A4 (E.G., MIDAZOLAM, TRIAZOLAM, ALPRAZOLAM). ADJUSTMENT OF BENZODIAZEPINE DOSAGE MAY BE NEEDED.', 'HMG-COA REDUCTASE INHIBITORS (STATINS) (CYP3A4 INHIBITION)', 'IN VITRO STUDIES DEMONSTRATED POTENTIAL FOR VORICONAZOLE TO INHIBIT METABOLISM (INCREASED PLASMA EXPOSURE)', 'FREQUENT MONITORING FOR ADVERSE EVENTS AND TOXICITY RELATED TO STATINS. INCREASED STATIN CONCENTRATIONS IN PLASMA HAVE BEEN ASSOCIATED WITH RHABDOMYOLYSIS. ADJUSTMENT OF THE STATIN DOSAGE MAY BE NEEDED.']